Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Binds penicillin-binding proteins and inhibits the final transpeptidation step of bacterial peptidoglycan cell-wall synthesis, producing bactericidal activity against susceptible organisms.
Indications / reported uses
Treatment of infections caused by cefixime-susceptible bacteria, including selected urinary-tract infections, otitis media, pharyngitis/tonsillitis and acute exacerbations of chronic bronchitis
Treatment of uncomplicated gonorrhoea only where recommended by current local antimicrobial guidance and susceptibility patterns; exact approved indications vary by jurisdiction
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Cefixime PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cefixime Permitted Daily Exposure (PDE) report (the Cefixime PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cefixime Occupational Exposure Limit (OEL) report (the Cefixime OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.